Clinical trials: Ocular Histoplasmosis, open to volunteers
Presumed Ocular Histoplasmosis
A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome
This study will evaluate the safety and effects, good or bad of faricimab (Vabysmo®), a drug that is approved by the U.S. Food and Drug Administration (FDA) for other retinal conditions, but its use is considered investigational…
- Trial name
- PLANE (NCT07695298)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Cincinnati Eye Institute, Southwest Ohio